Advertisement

Induction of Targeted Necrosis with HER2-Targeted Platinum(IV) Anticancer Prodrugs

  • Daniel Yuan Qiang WongEmail author
Chapter
  • 290 Downloads
Part of the Springer Theses book series (Springer Theses)

Abstract

Precision medicine in the form of molecularly-targeted therapies are now the frontline in the treatment of cancer, buoyed by tangible improvements in treatment tolerability and outcomes (Teicher in Mol Cancer Ther, pp. 7–40, 2005 [1]). Nonetheless, drug resistance against targeted therapies almost inevitably arises eventually after several treatment cycles.

Supplementary material

References

  1. 1.
    Teicher, B.A.: Molecular cancer therapeutics: will the promise be fulfilled? Mol. Cancer Ther., 7–40 (2005)Google Scholar
  2. 2.
    Shah, M.A., Schwartz, G.K.: Cell cycle-mediated drug resistance: an emerging concept in cancer therapy. Clin. Cancer Res. 7, 2168–2181 (2001)PubMedGoogle Scholar
  3. 3.
    Siddik, Z.H.: Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene 22, 7265–7279 (2003)CrossRefPubMedGoogle Scholar
  4. 4.
    Gerlinger, M., Rowan, A.J., Horswell, S., Larkin, J., Endesfelder, D., Gronroos, E., Martinez, P., Matthews, N., Stewart, A., Tarpey, P., Varela, I., Phillimore, B., Begum, S., McDonald, N.Q., Butler, A., Jones, D., Raine, K., Latimer, C., Santos, C.R., Nohadani, M., Eklund, A.C., Spencer-Dene, B., Clark, G., Pickering, L., Stamp, G., Gore, M., Szallasi, Z., Downward, J., Futreal, P.A., Swanton, C.: Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N. Engl. J. Med. 366, 883–892 (2012)CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Galluzzi, L., Vitale, I., Vacchelli, E., Kroemer, G.: Cell death signaling and anticancer therapy. Front. Oncol. 1 (2011)Google Scholar
  6. 6.
    Dinnen, R.D., Drew, L., Petrylak, D.P., Mao, Y., Cassai, N., Szmulewicz, J., Brandt-Rauf, P., Fine, R.L.: Activation of targeted Necrosis by a p53 Peptide: a novel death pathway that circumvents apoptotic resistance. J. Biol. Chem. 282, 26675–26686 (2007)CrossRefPubMedGoogle Scholar
  7. 7.
    Hu, X., Xuan, Y.: Bypassing cancer drug resistance by activating multiple death pathways—a proposal from the study of circumventing cancer drug resistance by induction of necroptosis. Cancer Lett. 259, 127–137 (2008)CrossRefPubMedGoogle Scholar
  8. 8.
    Rubin, I., Yarden, Y.: The basic biology of HER2. Ann. Oncol. 12, S3–S8 (2001)CrossRefPubMedGoogle Scholar
  9. 9.
    Jorgensen, J.T., Hersom, M.: HER2 as a prognostic marker in gastric cancer—a systematic analysis of data from the literature. J. Cancer 3, 137–144 (2012)CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Claret, F.X., Vu, T.T.: Trastuzumab: updated mechanisms of action and resistance in breast cancer. Front. Oncol. 2 (2012)Google Scholar
  11. 11.
    Park, B.-W., Zhang, H.-T., Wu, C., Berezov, A., Zhang, X., Dua, R., Wang, Q., Kao, G., O’Rourke, D.M., Greene, M.I., Murali, R.: Rationally designed anti-HER2/neu peptide mimetic disables P185HER2/neu tyrosine kinases in vitro and in vivo. Nat. Biotech. 18, 194–198 (2000)CrossRefGoogle Scholar
  12. 12.
    Berezov, A., Zhang, H.-T., Greene, M.I., Murali, R.: Disabling erbB receptors with rationally designed exocyclic mimetics of antibodies: structure−function analysis†. J. Med. Chem. 44, 2565–2574 (2001)CrossRefPubMedGoogle Scholar
  13. 13.
    Chin, C.F., Wong, D.Y.Q., Jothibasu, R., Ang, W.H.: Anticancer platinum (IV) prodrugs with novel modes of activity. Curr. Top. Med. Chem. 11, 2602–2612 (2011)CrossRefPubMedGoogle Scholar
  14. 14.
    Zhang, J.Z., Wexselblatt, E., Hambley, T.W., Gibson, D.: Pt (IV) analogs of oxaliplatin that do not follow the expected correlation between electrochemical reduction potential and rate of reduction by ascorbate. Chem. Commun. 48, 847–849 (2012)CrossRefGoogle Scholar
  15. 15.
    Wong, D.Y.Q., Lau, J.Y., Ang, W.H.: Harnessing chemoselective imine ligation for tethering bioactive molecules to platinum(iv) prodrugs. Dalton Trans. 41, 6104–6111 (2012)CrossRefPubMedGoogle Scholar
  16. 16.
    Wong, D.Y.Q., Yeo, C.H.F., Ang, W.H.: Immuno-chemotherapeutic platinum(IV) prodrugs of cisplatin as multimodal anticancer agents. Angew. Chem. Int. Ed. 53, 6752–6756 (2014)CrossRefGoogle Scholar
  17. 17.
    Zhang, J.Z., Bonnitcha, P., Wexselblatt, E., Klein, A.V., Najajreh, Y., Gibson, D., Hambley, T.W.: Facile preparation of mono-, di- and mixed-carboxylato platinum(IV) complexes for versatile anticancer prodrug design. Chem. Eur. J. 19, 1672–1676 (2013)CrossRefPubMedGoogle Scholar
  18. 18.
    Wilken, J., Webster, K., Maihle, N.: Trastuzumab sensitizes ovarian cancer cells to EGFR-targeted therapeutics. J. Ovarian Res. 3, 7 (2010)CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Boulikas, T., Vougiouka, M.: Cisplatin and platinum drugs at the molecular level (review). Oncol. Rep. 10, 1663–1682 (2003)PubMedGoogle Scholar
  20. 20.
    Martin, S.J., Reutelingsperger, C.P., McGahon, A.J., Rader, J.A., van Schie, R.C., LaFace, D.M., Green, D.R.: Early redistribution of plasma membrane phosphatidylserine is a general feature of apoptosis regardless of the initiating stimulus: inhibition by overexpression of Bcl-2 and Abl. J. Exp. Med. 182, 1545–1556 (1995)CrossRefPubMedGoogle Scholar
  21. 21.
    Denecker, G., Dooms, H., Van Loo, G., Vercammen, D., Grooten, J., Fiers, W., Declercq, W., Vandenabeele, P.: Phosphatidyl serine exposure during apoptosis precedes release of cytochrome c and decrease in mitochondrial transmembrane potential. FEBS Lett. 465, 47–52 (2000)CrossRefPubMedGoogle Scholar
  22. 22.
    Ziegler, U., Groscurth, P.: Morphological features of cell death. News Physiol. Sci. 19, 124–128 (2004)PubMedGoogle Scholar
  23. 23.
    Smardová, J., Pavlová, S., Svitáková, M., Grochová, D., Ravcuková, B.: Analysis of p53 status in human cell lines using a functional assay in yeast: Detection of new non-sense p53 mutation in codon 124. Oncol. Rep. 14, 901–907 (2005) Google Scholar
  24. 24.
    Lewis Phillips, G.D., Li, G., Dugger, D.L., Crocker, L.M., Parsons, K.L., Mai, E., Blättler, W.A., Lambert, J.M., Chari, R.V.J., Lutz, R.J., Wong, W.L.T., Jacobson, F.S., Koeppen, H., Schwall, R.H., Kenkare-Mitra, S.R., Spencer, S.D., Sliwkowski, M.X.: Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate. Cancer Res. 68, 9280–9290 (2008)CrossRefPubMedGoogle Scholar
  25. 25.
    Hanahan, D., Weinberg, R.: Hallmarks of cancer: the next generation. Cell 144, 646–674 (2011)CrossRefPubMedPubMedCentralGoogle Scholar
  26. 26.
    Maskey, D., Yousefi, S., Schmid, I., Zlobec, I., Perren, A., Friis, R., Simon, H.-U.: ATG5 is induced by DNA-damaging agents and promotes mitotic catastrophe independent of autophagy. Nat. Commun. 4 (2013)Google Scholar
  27. 27.
    Fuertes, M.A., Alonso, C., Perez, J.M.: Biochemical modulation of cisplatin mechanisms of action: enhancement of antitumor activity and circumvention of drug resistance. Chem. Rev. 103, 645–662 (2003)CrossRefPubMedGoogle Scholar
  28. 28.
    Wang, D., Lippard, S.J.: Cellular processing of platinum anticancer drugs. Nat. Rev. Drug Discov. 4, 307–320 (2005)CrossRefPubMedGoogle Scholar
  29. 29.
    Burgos, A., Ellames, G.J.: Synthesis of [3H2]-(R, R)-1,2-diaminocyclohexaneoxalatoplatinum(II), [3H2]-Oxaliplatin. J. Labelled Compd. Radiopharm. 41, 443–449 (1998)CrossRefGoogle Scholar
  30. 30.
    Fulmer, G.R., Miller, A.J.M., Sherden, N.H., Gottlieb, H.E., Nudelman, A., Stoltz, B.M., Bercaw, J.E., Goldberg, K.I.: NMR chemical shifts of trace impurities: common laboratory solvents, organics, and gases in deuterated solvents relevant to the organometallic chemist. Organometallics 29, 2176–2179 (2010)CrossRefGoogle Scholar
  31. 31.
    Gill, S.C., von Hippel, P.H.: Calculation of protein extinction coefficients from amino acid sequence data. Anal. Biochem. 182, 319–326 (1989)CrossRefPubMedGoogle Scholar
  32. 32.
    Park, G.Y., Wilson, J.J., Song, Y., Lippard, S.J.: Phenanthriplatin, a monofunctional DNA-binding platinum anticancer drug candidate with unusual potency and cellular activity profile. Proc. Natl. Acad. Sci. 109, 11987–11992 (2012)CrossRefPubMedGoogle Scholar

Copyright information

© Springer Nature Singapore Pte Ltd. 2018

Authors and Affiliations

  1. 1.Department of ChemistryNational University of SingaporeSingaporeSingapore

Personalised recommendations